Reporting owner · CIK 0002062834

Lippman Evan

SEC Form 4 history for the last 180 days across 1 company, 1 transaction and 1 filing.

EVP, BDEVP, Business DevelopmentTEVA PHARMACEUTICAL INDUSTRIES LTD
Open-market transaction mix0% buys0 buys · 1 sale

Period: Last 180 days

Trade dates in this period: Aug 17, 2026 – Aug 17, 2026

Transaction history, summary figures and purchase returns cover the last 180 days. Earlier activity is excluded from those sections.

Filings1Form 4 records
Buying$00 purchases
Selling$680k1 sale
Net value−$680kBuys minus sells · disclosed values

Latest insider transactions

Form 4 filings from the last 180 days.
Lippman Evan transactions · 20 per page
CompanyActivityDisclosed valueFiled (ET)
TEVATEVA PHARMACEUTICAL INDUSTRIES LTD
Executive Vice President · BD
EVP, BD
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$680kView disclosure →

Latest Form 4 facts

Quick context from source filings

Latest open-market transaction

The insider reported a sale at TEVA PHARMACEUTICAL INDUSTRIES LTD on Aug 17, 2026 valued at $680,291.28.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Monthly open-market activity

Last 1 reported month · purchases and sales

View exact monthly values
Monthly open-market source values
MonthPurchasesSalesBuy valueSale valueNet value
Aug 202601$0$680,291.28−$680,291.28

Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.

Ownership and transaction size

Ownership and ticket size

Average P/S size$680k
Median P/S size$680k
Direct1
Indirect0
Aug 17, 2026sale

Filing-only signals

Deterministic matches in this insider's history

Associated companies

Counts cover all available history, including outside the summary period

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
No open-market purchases in the last 180 days

A 90-day purchase return requires an open-market buy. None is recorded in the last 180 days. Purchases filed earlier are outside the visible history and are not included.

Disclosed ownership

How reported shareholdings evolved

Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.

1 observations · Aug 17, 2026 – Aug 17, 2026. Window ends at the latest available report, not today.

Selected observation · Aug 17, 202625,591 shares reported
Inspect transaction
View exact observations and source transactions
Transaction dateShares held afterFiledSource
Aug 17, 202625,591Aug 19, 2026View transaction

Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.

Lippman Evan Insider Activity FAQ

SEC Form 4 context

Who is Lippman Evan?

Lippman Evan is a reporting owner in SEC Form 4 filings with reporting owner CIK 0002062834.

Which companies has Lippman Evan reported transactions for?

TEVA PHARMACEUTICAL INDUSTRIES LTD

When was Lippman Evan's latest insider buy?

No open-market insider purchase is recorded in the last 180 days. Earlier filings are outside the visible history.

When was Lippman Evan's latest insider sale?

The insider reported a sale at TEVA PHARMACEUTICAL INDUSTRIES LTD on Aug 17, 2026 valued at $680,291.28.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.